Literature DB >> 17715332

Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria.

M Victoria Delpino1, Silvia M Estein, Carlos A Fossati, Pablo C Baldi.   

Abstract

Previous findings indicate that Brucella antigens and those from nonpathogenic alphaproteobacteria (NPAP) are cross-recognized by the immune system. We hypothesized that immunization with NPAP would protect mice from Brucella infection. Mice were immunized subcutaneously with heat-killed Ochrobactrum anthropi, Sinorhizobium meliloti, Mesorhizobium loti, Agrobacterium tumefaciens, or Brucella melitensis H38 (standard positive control) before intravenous challenge with Brucella abortus 2308. Cross-reacting serum antibodies against Brucella antigens were detected at the moment of challenge in all NPAP-immunized mice. Thirty days after B. abortus challenge, splenic CFU counts were significantly lower in mice immunized with O. anthropi, M. loti, and B. melitensis H38 than in the phosphate-buffered saline controls (protection levels were 0.80, 0.66, and 1.99 log units, respectively). In mice immunized intraperitoneally with cytosoluble extracts from NPAP or Brucella abortus, protection levels were 1.58 for the latter, 0.63 for O. anthropi, and 0.40 for M. loti. To test whether the use of live NPAP would increase protection further, mice were both immunized and challenged by the oral route. Immunization with NPAP induced a significant increase in serum immunoglobulin G (IgG), but not serum or fecal IgA, against Brucella antigens. After challenge, anti-Brucella IgA increased significantly in the sera and feces of mice orally immunized with O. anthropi. For all NPAP, protection levels were higher than those obtained with systemic immunizations but were lower than those obtained by oral immunization with heat-killed B. abortus. These results show that immunization with NPAP, especially O. anthropi, confers partial protection against Brucella challenge. However, such protection is lower than that conferred by immunization with whole Brucella or its cytosoluble fraction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17715332      PMCID: PMC2168122          DOI: 10.1128/CVI.00459-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  30 in total

Review 1.  What makes the rhizobia-legume symbiosis so special?

Authors:  A M Hirsch; M R Lum; J A Downie
Journal:  Plant Physiol       Date:  2001-12       Impact factor: 8.340

Review 2.  Partners-in-infection: host proteins involved in the transformation of plant cells by Agrobacterium.

Authors:  Tzvi Tzfira; Vitaly Citovsky
Journal:  Trends Cell Biol       Date:  2002-03       Impact factor: 20.808

3.  Epidemiology and control of brucellosis in China.

Authors:  Shang Deqiu; Xiao Donglou; Yin Jiming
Journal:  Vet Microbiol       Date:  2002-12-20       Impact factor: 3.293

Review 4.  Brucella evolution and taxonomy.

Authors:  Edgardo Moreno; Axel Cloeckaert; Ignacio Moriyón
Journal:  Vet Microbiol       Date:  2002-12-20       Impact factor: 3.293

5.  Recombinant Ochrobactrum anthropi expressing Brucella abortus Cu,Zn superoxide dismutase protects mice against B. abortus infection only after switching of immune responses to Th1 type.

Authors:  Yongqun He; Ramesh Vemulapalli; Gerhardt G Schurig
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 6.  Agrobacterium radiobacter bacteremia in pediatric patients: case report and review.

Authors:  Rene A Amaya; Morven S Edwards
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

7.  Identification of the Brucella melitensis vaccine strain Rev.1 in animals and humans in Israel by PCR analysis of the PstI site polymorphism of its omp2 gene.

Authors:  Svetlana Bardenstein; Michal Mandelboim; Thomas A Ficht; Miriam Baum; Menachem Banai
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

8.  Immunogenicity of the Brucella melitensis recombinant ribosome recycling factor-homologous protein and its cDNA.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Guillermo H Giambartolomei; Silvia Estein; Laura Bruno; Axel Cloeckaert; Raul A Bowden; Moisés Spitz; Carlos A Fossati
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

9.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

10.  The Brucella suis genome reveals fundamental similarities between animal and plant pathogens and symbionts.

Authors:  Ian T Paulsen; Rekha Seshadri; Karen E Nelson; Jonathan A Eisen; John F Heidelberg; Timothy D Read; Robert J Dodson; Lowell Umayam; Lauren M Brinkac; Maureen J Beanan; Sean C Daugherty; Robert T Deboy; A Scott Durkin; James F Kolonay; Ramana Madupu; William C Nelson; Bola Ayodeji; Margaret Kraul; Jyoti Shetty; Joel Malek; Susan E Van Aken; Steven Riedmuller; Herve Tettelin; Steven R Gill; Owen White; Steven L Salzberg; David L Hoover; Luther E Lindler; Shirley M Halling; Stephen M Boyle; Claire M Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-23       Impact factor: 11.205

View more
  4 in total

1.  Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.

Authors:  Karina A Pasquevich; Silvia M Estein; Clara García Samartino; Clara García Samartino; Astrid Zwerdling; Lorena M Coria; Paula Barrionuevo; Carlos A Fossati; Guillermo H Giambartolomei; Juliana Cassataro
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

Review 2.  What have we learned from brucellosis in the mouse model?

Authors:  María-Jesús Grilló; José María Blasco; Jean Pierre Gorvel; Ignacio Moriyón; Edgardo Moreno
Journal:  Vet Res       Date:  2012-04-13       Impact factor: 3.683

3.  Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development.

Authors:  Samantha Sayers; Guerlain Ulysse; Zuoshuang Xiang; Yongqun He
Journal:  J Biomed Biotechnol       Date:  2012-03-13

Review 4.  Immune Response to Mucosal Brucella Infection.

Authors:  Rubén López-Santiago; Ana Beatriz Sánchez-Argáez; Liliana Gabriela De Alba-Núñez; Shantal Lizbeth Baltierra-Uribe; Martha Cecilia Moreno-Lafont
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.